Rubius Therapeutics plunges as lead drug's cancer trial data disappoints

Rubius Therapeutics

08/04/2022 19:49

** Drug developer's  RUBY.O  shares dive 46% to $3.16 in
afternoon trade as its lead drug candidate's cancer trial
results disappoint 
    ** RUBY's updated early-stage trial data from its drug,
RTX-240, in patients with advanced solid tumors showed the drug
controlled disease in only 10 of 27 evaluated patients, of which
three showed partial responses  urn:newsml:reuters.com:*:nGNXZDlVY
    ** Adds final results from another trial in patients with
acute myeloid leukemia showed three of 17 patients in the trial
had grade 3 or 4 adverse events related to the treatment, which
are among the most severe side-effects, before death
    ** Including session losses, stock down 67% YTD

 (Reporting by Leroy Leo in Bengaluru)
 ((Leroy.Dsouza@thomsonreuters.com ; Twitter: https://twitter.com/LeroyLeo7;))